Strand Life Sciences
Bengaluru, India· Est.
Genomics data‑platform enabling AI‑driven diagnostics and drug discovery for oncology and rare diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Genomics data‑platform enabling AI‑driven diagnostics and drug discovery for oncology and rare diseases.
OncologyRare DiseaseGenetics & Genomics
Technology Platform
An integrated genomics data platform that combines NGS/PCR diagnostics, AI‑assisted variant interpretation, and single‑cell/spatial transcriptomics, delivered via regulatory‑compliant software and a CAP‑certified lab.
Opportunities
Expansion of AI‑driven variant interpretation services and scaling of single‑cell/spatial transcriptomics offerings can capture growing demand for precision‑medicine data solutions.
Risk Factors
Intense competition from global sequencing and analytics firms and the need to continuously meet stringent regulatory and data‑privacy standards pose significant challenges.
Competitive Landscape
Key competitors include Illumina, Invitae, and Bina Technologies; Strand differentiates itself through its end‑to‑end service model, AI‑assisted interpretation, and strong regulatory compliance expertise.